4DMedical Ltd (4DX.AU) saw its shares plummet 5.13% during intraday trading on Thursday, as investors reacted to news of potential regulatory developments affecting the company.
The medical technology firm has sought a trading halt pending an announcement regarding the implications of a US Congress Bill for its business operations. This development has created uncertainty in the market, leading to the significant price decline.
According to company announcements, the US Congress Bill in question directs the Department of Veterans Affairs (VA) to adopt 4D lung imaging technology, which represents both a potential opportunity and source of uncertainty for 4DMedical's future business prospects.